N, P., LA, F., R, V., A, V., G, A., & G, C. (2026). Long-term impact of Elexacaftor/Tezacaftor/ivacaftor on pulmonary, nutritional and metabolic outcomes in homozygous F508del cystic fibrosis patients: A real-world cohort study. British journal of clinical pharmacology, 92(6), 1822. https://doi.org/10.1002/bcp.70460
Παραπομπή σε μορφή Chicago (17η εκδ.)N, Perrotta, Fiorito LA, Vescovo R, Virgilio A, Amato G, και Cimino G. "Long-term Impact of Elexacaftor/Tezacaftor/ivacaftor on Pulmonary, Nutritional and Metabolic Outcomes in Homozygous F508del Cystic Fibrosis Patients: A Real-world Cohort Study." British Journal of Clinical Pharmacology 92, no. 6 (2026): 1822. https://doi.org/10.1002/bcp.70460.
Παραπομπή σε μορφή MLA (9th εκδ.)N, Perrotta, et al. "Long-term Impact of Elexacaftor/Tezacaftor/ivacaftor on Pulmonary, Nutritional and Metabolic Outcomes in Homozygous F508del Cystic Fibrosis Patients: A Real-world Cohort Study." British Journal of Clinical Pharmacology, vol. 92, no. 6, 2026, p. 1822, https://doi.org/10.1002/bcp.70460.